Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal oxytocin for alcohol use disorder
NCT03878316Phase 2Completed
- Sponsor
- National Institute on Alcohol Abuse and Alcoholism
- Start
- Jun 2022
- Primary completion
- Oct 2023
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of oxytocin nasal spray in alcohol use disorder (AUD), sponsored by National Institute on Alcohol Abuse and Alcoholism. Primary endpoint: Weekly Percentage of Heavy Drinking Days at 12 weeks. Started Jun 2022; status: completed.
02
Drugs
oxytocin nasal spray
03
Conditions
alcohol use disorder (AUD)
Beyond the preview
Go deeper on NCT03878316.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03878316.